Sarepta Therapeutics (SRPT) Tops Q2 EPS by 57c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Evercore ISI Upgrades Sarepta Therapeutics (SRPT) to Outperform
August 8, 2024 8:18 AM EDTEvercore ISI analyst Gavin Clark-Gartner upgraded Sarepta Therapeutics (NASDAQ: SRPT) from In Line to Outperform with a price target of $179.00 (from $185.00).
For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.
Shares of Sarepta Therapeutics closed at $140.06 yesterday.
... MoreSarepta Therapeutics (SRPT) PT Lowered to $181 at RBC Capital
August 8, 2024 6:27 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $181.00 (from $182.00) while maintaining a Outperform rating.
The analyst comments "SRPT reported 2Q earnings, and we had the chance to follow up with mgmt afterwards. We came away... More
